Alternating Sunitinib, Everolimus Not Effective for Advanced Renal Cell Carcinoma

Share this content:
Alternating regimen of sunitinib and everolimus lacked clinical activity in the treatment of patients with advanced renal cell carcinoma.
Alternating regimen of sunitinib and everolimus lacked clinical activity in the treatment of patients with advanced renal cell carcinoma.

According to a new study published in the journal Annals of Oncology, researchers in Australia have found that an alternating regimen of sunitinib and everolimus lacked clinical activity, despite being feasible and safe, in the treatment of patients with advanced renal cell carcinoma.

For the single-arm, two-stage, multicenter, phase 2 study, researchers enrolled 55 patients with favorable or intermediate risk advanced renal cell carcinoma and gave them 12-week cycles of sunitinib 50mg daily for 4 weeks on, 2 weeks off, alternating with everolimus 10mg daily for 5 weeks on, 1 week off, until disease progression or unacceptable toxicity.

Results showed a 6-month progression-free survival rate of 53% (95% CI: 40-66) and a tumor response rate of 13% (95% CI: 2-22).

RELATED: Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions

All patients who experienced a response achieved a partial response. After a median follow-up of 20 months, the median progression-free survival was 8 months (95% CI: 5-10) and the median overall survival was 17 months (95% CI: 12 to undefined). In regard to safety, all adverse events were consistent with previous studies for each agent.

The findings suggest that the current approach of continuing anti-VEGF therapy until disease progression or unacceptable toxicity before changing treatment should be continued in clinical practice.

References

  1. Davis ID, et al. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Ann Oncol. February 20, 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv078

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters